Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis
Abstract Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study the safety and clinical effectiveness of advanced IBD therapies in patients with end stage renal disease (ESRD), defined as an eGFR <15 mL/min...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | JGH Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jgh3.13015 |
| _version_ | 1827394953353887744 |
|---|---|
| author | Patrick Hilley Danny Con Matthew C. Choy Ashish Srinivasan Peter De Cruz |
| author_facet | Patrick Hilley Danny Con Matthew C. Choy Ashish Srinivasan Peter De Cruz |
| author_sort | Patrick Hilley |
| collection | DOAJ |
| description | Abstract Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study the safety and clinical effectiveness of advanced IBD therapies in patients with end stage renal disease (ESRD), defined as an eGFR <15 mL/min/1.73m2. Upadacitinib, a selective oral Janus kinase (JAK) 1 inhibitor, has demonstrated efficacy in the management of moderate to severe ulcerative colitis. There is also emerging data indicating that JAK inhibition may be clinically effective in the setting of steroid‐refractory acute severe ulcerative colitis (ASUC). There is, however, a lack of “real‐world” data documenting the use of JAK inhibitors in patients with ESRD. Here, we report the use of upadacitinib in a patient with ESRD for the management of steroid‐refractory ASUC, demonstrating, for the first time, the safe and clinically effective use of upadacitinib in this population. |
| first_indexed | 2024-03-08T18:24:44Z |
| format | Article |
| id | doaj.art-854f3dd6b2274409b50caea80e26b2a0 |
| institution | Directory Open Access Journal |
| issn | 2397-9070 |
| language | English |
| last_indexed | 2024-03-08T18:24:44Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | JGH Open |
| spelling | doaj.art-854f3dd6b2274409b50caea80e26b2a02023-12-30T16:05:17ZengWileyJGH Open2397-90702023-12-017121012101510.1002/jgh3.13015Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitisPatrick Hilley0Danny Con1Matthew C. Choy2Ashish Srinivasan3Peter De Cruz4Department of Gastroenterology Austin Health Heidelberg Victoria AustraliaDepartment of Gastroenterology Austin Health Heidelberg Victoria AustraliaDepartment of Gastroenterology Austin Health Heidelberg Victoria AustraliaDepartment of Gastroenterology Austin Health Heidelberg Victoria AustraliaDepartment of Gastroenterology Austin Health Heidelberg Victoria AustraliaAbstract Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study the safety and clinical effectiveness of advanced IBD therapies in patients with end stage renal disease (ESRD), defined as an eGFR <15 mL/min/1.73m2. Upadacitinib, a selective oral Janus kinase (JAK) 1 inhibitor, has demonstrated efficacy in the management of moderate to severe ulcerative colitis. There is also emerging data indicating that JAK inhibition may be clinically effective in the setting of steroid‐refractory acute severe ulcerative colitis (ASUC). There is, however, a lack of “real‐world” data documenting the use of JAK inhibitors in patients with ESRD. Here, we report the use of upadacitinib in a patient with ESRD for the management of steroid‐refractory ASUC, demonstrating, for the first time, the safe and clinically effective use of upadacitinib in this population.https://doi.org/10.1002/jgh3.13015acute severe ulcerative colitisend stage renal diseasejanus kinase inhibitorupadacitinib |
| spellingShingle | Patrick Hilley Danny Con Matthew C. Choy Ashish Srinivasan Peter De Cruz Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis JGH Open acute severe ulcerative colitis end stage renal disease janus kinase inhibitor upadacitinib |
| title | Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis |
| title_full | Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis |
| title_fullStr | Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis |
| title_full_unstemmed | Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis |
| title_short | Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis |
| title_sort | upadacitinib in end stage renal disease a case of acute severe ulcerative colitis |
| topic | acute severe ulcerative colitis end stage renal disease janus kinase inhibitor upadacitinib |
| url | https://doi.org/10.1002/jgh3.13015 |
| work_keys_str_mv | AT patrickhilley upadacitinibinendstagerenaldiseaseacaseofacutesevereulcerativecolitis AT dannycon upadacitinibinendstagerenaldiseaseacaseofacutesevereulcerativecolitis AT matthewcchoy upadacitinibinendstagerenaldiseaseacaseofacutesevereulcerativecolitis AT ashishsrinivasan upadacitinibinendstagerenaldiseaseacaseofacutesevereulcerativecolitis AT peterdecruz upadacitinibinendstagerenaldiseaseacaseofacutesevereulcerativecolitis |